{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:26:06Z","timestamp":1772097966165,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02328-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:01:15Z","timestamp":1764252075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Life Course Approach to Familial Hypercholesterolemia"],"prefix":"10.1007","volume":"27","author":[{"given":"Marcio H.","family":"Miname","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Del","family":"Castanhel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie H.","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"6","key":"2328_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","volume":"72","author":"AC Sturm","year":"2018","unstructured":"Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for Familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72(6):662\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.044.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2328_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 2020;141(22):1742\u201359. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044795.","journal-title":"Circulation"},{"issue":"25","key":"2328_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277. https:\/\/doi.org\/10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"issue":"22","key":"2328_CR4","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167\u201392. https:\/\/doi.org\/10.1161\/CIR.0000000000000297.","journal-title":"Circulation"},{"key":"2328_CR5","doi-asserted-by":"crossref","unstructured":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ (Clinical Res ed). 1991;303(6807):893\u20136.","DOI":"10.1136\/bmj.303.6807.893"},{"issue":"2","key":"2328_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","volume":"72","author":"RR Williams","year":"1993","unstructured":"Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous Familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171\u20136.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2328_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/ncpcardio0836","volume":"4","author":"AK Soutar","year":"2007","unstructured":"Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214. https:\/\/doi.org\/10.1038\/ncpcardio0836.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"1","key":"2328_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","volume":"16","author":"AJ Berberich","year":"2019","unstructured":"Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019;16(1):9\u201320. https:\/\/doi.org\/10.1038\/s41569-018-0052-6.","journal-title":"Nat Rev Cardiol"},{"key":"2328_CR9","unstructured":"Ison HE, Clarke SL, Knowles JW. Familial Hypercholesterolemia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews((R)). Seattle (WA)1993."},{"issue":"9874","key":"2328_CR10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","volume":"381","author":"PJ Talmud","year":"2013","unstructured":"Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381(9874):1293\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(12)62127-8.","journal-title":"Lancet"},{"issue":"7","key":"2328_CR11","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.numecd.2021.04.006","volume":"31","author":"L Antoniazzi","year":"2021","unstructured":"Antoniazzi L, Arroyo-Olivares R, Bittencourt MS, Tada MT, Lima I, Jannes CE, et al. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2021;31(7):2014\u201322. https:\/\/doi.org\/10.1016\/j.numecd.2021.04.006.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"22","key":"2328_CR12","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.520.","journal-title":"J Am Coll Cardiol"},{"issue":"10312","key":"2328_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","volume":"398","author":"Collaboration EASFHS","year":"2021","unstructured":"Collaboration EASFHS. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(21)01122-3.","journal-title":"Lancet"},{"issue":"2","key":"2328_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.atherosclerosis.2014.05.917","volume":"235","author":"I Narverud","year":"2014","unstructured":"Narverud I, Retterstol K, Iversen PO, Halvorsen B, Ueland T, Ulven SM, et al. Markers of atherosclerotic development in children with Familial hypercholesterolemia: a literature review. Atherosclerosis. 2014;235(2):299\u2013309. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.05.917.","journal-title":"Atherosclerosis"},{"issue":"9","key":"2328_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S2213-8587(23)00156-0","volume":"11","author":"LM de Boer","year":"2023","unstructured":"de Boer LM, Wiegman A, Kroon J, Tsimikas S, Yeang C, Peletier MC, et al. Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study. Lancet Diabetes Endocrinol. 2023;11(9):667\u201374. https:\/\/doi.org\/10.1016\/S2213-8587(23)00156-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"2328_CR16","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1016\/j.jacc.2015.09.087","volume":"66","author":"GR Ten Kate","year":"2015","unstructured":"Ten Kate GR, Bos S, Dedic A, Neefjes LA, Kurata A, Langendonk JG, et al. Increased aortic valve calcification in Familial hypercholesterolemia: Prevalence, Extent, and associated risk factors. J Am Coll Cardiol. 2015;66(24):2687\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.087.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2328_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5114\/pedm.2022.116112","volume":"28","author":"S Ziolkowska","year":"2022","unstructured":"Ziolkowska S, Kijek N, Zendran I, Szuster E, Barg E. Familial hypercholesterolemia - treatment update in children, systematic review. Pediatr Endocrinol Diabetes Metab. 2022;28(2):152\u201361. https:\/\/doi.org\/10.5114\/pedm.2022.116112.","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"issue":"32","key":"2328_CR18","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehu274.","journal-title":"Eur Heart J"},{"issue":"36","key":"2328_CR19","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425\u201337. https:\/\/doi.org\/10.1093\/eurheartj\/ehv157.","journal-title":"Eur Heart J"},{"key":"2328_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf352","author":"J Kafol","year":"2025","unstructured":"Kafol J, Miranda B, Sikonja R, Sikonja J, Wiegman A, Medeiros AM, et al. Proposal of a Familial hypercholesterolemia pediatric diagnostic score (FH-PeDS). Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf352.","journal-title":"Eur J Prev Cardiol"},{"issue":"7620","key":"2328_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/bmj.39300.616076.55","volume":"335","author":"DS Wald","year":"2007","unstructured":"Wald DS, Bestwick JP, Wald NJ. Child-parent screening for Familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;335(7620):599. https:\/\/doi.org\/10.1136\/bmj.39300.616076.55.","journal-title":"BMJ"},{"issue":"12","key":"2328_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","volume":"20","author":"GF Watts","year":"2023","unstructured":"Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International atherosclerosis society guidance for implementing best practice in the care of Familial hypercholesterolaemia. Nat Rev Cardiol. 2023;20(12):845\u201369. https:\/\/doi.org\/10.1038\/s41569-023-00892-0.","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"2328_CR23","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"2328_CR24","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"key":"2328_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100611","volume":"17","author":"K Nasir","year":"2024","unstructured":"Nasir K, Mszar R, Cainzos-Achirica M, Grandhi GR, Tromp TR, Alonso R, et al. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: a multi-national study. Am J Prev Cardiol. 2024;17:100611. https:\/\/doi.org\/10.1016\/j.ajpc.2023.100611.","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"2328_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.atherosclerosis.2009.06.006","volume":"207","author":"O Guardamagna","year":"2009","unstructured":"Guardamagna O, Abello F, Saracco P, Baracco V, Rolfo E, Pirro M. Endothelial activation, inflammation and premature atherosclerosis in children with Familial dyslipidemia. Atherosclerosis. 2009;207(2):471\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.06.006.","journal-title":"Atherosclerosis"},{"issue":"7","key":"2328_CR27","doi-asserted-by":"publisher","first-page":"e038458","DOI":"10.1161\/JAHA.124.038458","volume":"14","author":"SS Gidding","year":"2025","unstructured":"Gidding SS, Blom DJ, McCrindle B, Ramaswami U, Santos RD, Watts GF, et al. Life course approach for managing Familial hypercholesterolemia. J Am Heart Association. 2025;14(7):e038458. https:\/\/doi.org\/10.1161\/JAHA.124.038458.","journal-title":"J Am Heart Association"},{"issue":"5","key":"2328_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1542\/peds.2009-2107C","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents, National Heart L, Blood I","year":"2011","unstructured":"Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents, National Heart L, Blood I. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(5):213\u201356. https:\/\/doi.org\/10.1542\/peds.2009-2107C.","journal-title":"Pediatrics"},{"key":"2328_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.athplu.2024.10.003","volume":"58","author":"EB Lovheim","year":"2024","unstructured":"Lovheim EB, Retterstol K, Narverud I, Bogsrud MP, Halvorsen B, Ueland T, et al. Adherence to the healthy nordic food index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous Familial hypercholesterolemia. Atheroscler Plus. 2024;58:38\u201345. https:\/\/doi.org\/10.1016\/j.athplu.2024.10.003.","journal-title":"Atheroscler Plus"},{"issue":"6","key":"2328_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jpeds.2005.01.055","volume":"146","author":"WB Strong","year":"2005","unstructured":"Strong WB, Malina RM, Blimkie CJ, Daniels SR, Dishman RK, Gutin B, et al. Evidence based physical activity for school-age youth. J Pediatr. 2005;146(6):732\u20137. https:\/\/doi.org\/10.1016\/j.jpeds.2005.01.055.","journal-title":"J Pediatr"},{"issue":"16","key":"2328_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","volume":"381","author":"IK Luirink","year":"2019","unstructured":"Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1816454.","journal-title":"N Engl J Med"},{"issue":"14","key":"2328_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","volume":"383","author":"RD Santos","year":"2020","unstructured":"Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383(14):1317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2019910.","journal-title":"N Engl J Med"},{"issue":"3","key":"2328_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","volume":"178","author":"RD Santos","year":"2024","unstructured":"Santos RD, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA Pediatr. 2024;178(3):283\u201393. https:\/\/doi.org\/10.1001\/jamapediatrics.2023.6477.","journal-title":"JAMA Pediatr"},{"issue":"7","key":"2328_CR34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1007\/s12325-019-00985-8","volume":"36","author":"T Ben-Omran","year":"2019","unstructured":"Ben-Omran T, Masana L, Kolovou G, Ariceta G, Novoa FJ, Lund AM, et al. Real-World outcomes with lomitapide use in paediatric patients with homozygous Familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786\u2013811. https:\/\/doi.org\/10.1007\/s12325-019-00985-8.","journal-title":"Adv Ther"},{"issue":"12","key":"2328_CR35","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","volume":"12","author":"L Masana","year":"2024","unstructured":"Masana L, Zambon A, Schmitt CP, Taylan C, Driemeyer J, Cohen H, et al. Lomitapide for the treatment of paediatric patients with homozygous Familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study. Lancet Diabetes Endocrinol. 2024;12(12):880\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(24)00233-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2328_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","volume":"198","author":"GR Thompson","year":"2008","unstructured":"Thompson GR, Group H-ULAW. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247\u201355. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.02.009.","journal-title":"Atherosclerosis"},{"issue":"45","key":"2328_CR37","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478\u2013a90. https:\/\/doi.org\/10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J"},{"issue":"1","key":"2328_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"10","key":"2328_CR39","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","volume":"4","author":"RD Santos","year":"2016","unstructured":"Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016;4(10):850\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(16)30041-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2328_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/2047487314533218","volume":"22","author":"GF Watts","year":"2015","unstructured":"Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015;22(7):849\u201354. https:\/\/doi.org\/10.1177\/2047487314533218.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2328_CR41","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","volume":"30","author":"P Primary","year":"2014","unstructured":"Primary P, Genest J, Hegele RA, Bergeron J, Brophy J, Carpentier A, et al. Canadian cardiovascular society position statement on Familial hypercholesterolemia. Can J Cardiol. 2014;30(12):1471\u201381. https:\/\/doi.org\/10.1016\/j.cjca.2014.09.028.","journal-title":"Can J Cardiol"},{"issue":"5","key":"2328_CR42","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jacl.2017.07.008","volume":"11","author":"M Paquette","year":"2017","unstructured":"Paquette M, Brisson D, Dufour R, Khoury E, Gaudet D, Baass A. Cardiovascular disease in familial hypercholesterolemia: validation and refinement of the Montreal-FH-SCORE. J Clin Lipidol. 2017;11(5):1161-7 e3. https:\/\/doi.org\/10.1016\/j.jacl.2017.07.008.","journal-title":"J Clin Lipidol"},{"issue":"22","key":"2328_CR43","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","volume":"135","author":"L Perez de Isla","year":"2017","unstructured":"Perez de Isla L, Alonso R, Mata N, Fernandez-Perez C, Muniz O, Diaz-Diaz JL, et al. Predicting cardiovascular events in Familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial hypercholesterolemia cohort Study). Circulation. 2017;135(22):2133\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024541.","journal-title":"Circulation"},{"issue":"10","key":"2328_CR44","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","volume":"41","author":"M Paquette","year":"2021","unstructured":"Paquette M, Bernard S, Cariou B, Hegele RA, Genest J, Trinder M, et al. Familial Hypercholesterolemia-Risk-Score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021;41(10):2632\u201340. https:\/\/doi.org\/10.1161\/ATVBAHA.121.316106.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2328_CR45","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jcmg.2018.09.019","volume":"12","author":"MH Miname","year":"2019","unstructured":"Miname MH, Bittencourt MS, Moraes SR, Alves RIM, Silva PRS, Jannes CE, et al. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. JACC Cardiovascular imaging. 2019;12(9):1797\u2013804. https:\/\/doi.org\/10.1016\/j.jcmg.2018.09.019.","journal-title":"JACC Cardiovascular imaging"},{"issue":"12","key":"2328_CR46","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.jcmg.2021.06.011","volume":"14","author":"A Gallo","year":"2021","unstructured":"Gallo A, Perez de Isla L, Charriere S, Vimont A, Alonso R, Muniz-Grijalvo O, et al. The added value of coronary calcium score in predicting cardiovascular events in Familial hypercholesterolemia. JACC Cardiovasc Imaging. 2021;14(12):2414\u201324. https:\/\/doi.org\/10.1016\/j.jcmg.2021.06.011.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"2328_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oead046","volume":"3","author":"H Tada","year":"2023","unstructured":"Tada H, Kojima N, Yamagami K, Nomura A, Nohara A, Usui S, et al. Coronary artery calcium among patients with heterozygous familial hypercholesterolaemia. Eur Heart J Open. 2023;3(3):oead046. https:\/\/doi.org\/10.1093\/ehjopen\/oead046.","journal-title":"Eur Heart J Open"},{"key":"2328_CR48","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2019.09.014","volume":"292","author":"PB Sandesara","year":"2020","unstructured":"Sandesara PB, Mehta A, O\u2019Neal WT, Kelli HM, Sathiyakumar V, Martin SS, et al. <article-title update=\"added\">Clinical significance of zero coronary artery calcium in individuals with LDL cholesterol \u2265190\u202fmg\/dL: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2020;292:224\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.09.014.","journal-title":"Atherosclerosis"},{"issue":"3","key":"2328_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ehjci\/jez280","volume":"21","author":"MH Miname","year":"2020","unstructured":"Miname MH, Bittencourt MS, Pereira AC, Jannes CE, Krieger JE, Nasir K, et al. Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia. Eur Heart J Cardiovasc Imaging. 2020;21(3):251\u20137. https:\/\/doi.org\/10.1093\/ehjci\/jez280.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"2328_CR50","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.jcmg.2021.06.013","volume":"14","author":"RD Santos","year":"2021","unstructured":"Santos RD, Shapiro MD. Coronary Artery Calcification and Risk Stratification in Familial Hypercholesterolemia: moving forward but not there yet. JACC Cardiovascular imaging. 2021;14(12):2425\u20138. https:\/\/doi.org\/10.1016\/j.jcmg.2021.06.013.","journal-title":"JACC Cardiovascular imaging"},{"issue":"19","key":"2328_CR51","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","volume":"63","author":"R Alonso","year":"2014","unstructured":"Alonso R, Andres E, Mata N, Fuentes-Jimenez F, Badimon L, Lopez-Miranda J, et al. Lipoprotein(a) levels in Familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63(19):1982\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.063.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2328_CR52","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/j.jacl.2023.12.005","volume":"18","author":"PB Duell","year":"2024","unstructured":"Duell PB, Banach M, Catapano AL, Laufs U, Mancini GBJ, Ray KK, et al. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials. J Clin Lipidol. 2024;18(2):e153\u201365. https:\/\/doi.org\/10.1016\/j.jacl.2023.12.005.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2328_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.36660\/abc.20210788","volume":"117","author":"MCO Izar","year":"2021","unstructured":"Izar MCO, Giraldez VZR, Bertolami A, Santos Filho RDD, Lottenberg AM, Assad MHV, et al. Update of the Brazilian guideline for Familial hypercholesterolemia \u2013\u20092021. Arq Bras Cardiol. 2021;117(4):782\u2013844. https:\/\/doi.org\/10.36660\/abc.20210788.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"2328_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11883-024-01269-5","volume":"27","author":"DJ Blom","year":"2025","unstructured":"Blom DJ, Marais AD, Raal FJ. Homozygous familial hypercholesterolemia treatment: new developments. Curr Atheroscler Rep. 2025;27(1):22. https:\/\/doi.org\/10.1007\/s11883-024-01269-5.","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"2328_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCULATIONAHA.123.067241","volume":"149","author":"RD Santos","year":"2024","unstructured":"Santos RD, Cuchel M. LDL-C-lowering therapies for adults and children with homozygous familial hypercholesterolemia: challenges and successes. Circulation. 2024;149(5):363\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067241.","journal-title":"Circulation"},{"issue":"6","key":"2328_CR56","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","volume":"75","author":"RD Santos","year":"2020","unstructured":"Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(6):565\u201374. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.020.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2328_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","volume":"76","author":"DJ Blom","year":"2020","unstructured":"Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, et al. Efficacy and safety of Alirocumab in adults with homozygous Familial hypercholesterolemia: the ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76(2):131\u201342. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.027.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2328_CR58","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"issue":"3","key":"2328_CR59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jca.21470","volume":"31","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical Practice-Evidence-Based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin Apher. 2016;31(3):149\u201362. https:\/\/doi.org\/10.1002\/jca.21470.","journal-title":"J Clin Apher"},{"key":"2328_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf411","author":"C Gurevitz","year":"2025","unstructured":"Gurevitz C, Bajaj A, Khera AV, Do R, Schunkert H, Musunuru K, et al. Gene therapy and genome editing for lipoprotein disorders. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf411.","journal-title":"Eur Heart J"},{"issue":"6","key":"2328_CR61","doi-asserted-by":"publisher","first-page":"e001236","DOI":"10.1161\/JAHA.114.001236","volume":"3","author":"L Mundal","year":"2014","unstructured":"Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierod MB, et al. Mortality among patients with Familial hypercholesterolemia: a registry-based study in Norway, 1992\u20132010. J Am Heart Assoc. 2014;3(6):e001236. https:\/\/doi.org\/10.1161\/JAHA.114.001236.","journal-title":"J Am Heart Assoc"},{"issue":"10263","key":"2328_CR62","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","volume":"396","author":"MB Mortensen","year":"2020","unstructured":"Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)32233-9.","journal-title":"Lancet"},{"issue":"7","key":"2328_CR63","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.numecd.2022.03.028","volume":"32","author":"T Melnes","year":"2022","unstructured":"Melnes T, Bogsrud MP, Thorsen I, Fossum J, Christensen JJ, Narverud I, et al. What characterizes event-free elderly FH patients? A comprehensive lipoprotein profiling. Nutr Metab Cardiovasc Dis. 2022;32(7):1651\u201360. https:\/\/doi.org\/10.1016\/j.numecd.2022.03.028.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2328_CR64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.12.012","volume":"318","author":"ER Coutinho","year":"2021","unstructured":"Coutinho ER, Miname MH, Rocha VZ, Bittencourt MS, Jannes CE, Tada MT, et al. Familial hypercholesterolemia and cardiovascular disease in older individuals. Atherosclerosis. 2021;318:32\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.12.012.","journal-title":"Atherosclerosis"},{"key":"2328_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2022.12.007","volume":"365","author":"ER Coutinho","year":"2023","unstructured":"Coutinho ER, Miname MH, Rocha VZ, Bittencourt MS, Jannes CE, Krieger JE, et al. Cardiovascular disease onset in old people with severe hypercholesterolemia. Atherosclerosis. 2023;365:9\u201314. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.12.007.","journal-title":"Atherosclerosis"},{"key":"2328_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010231","author":"C Antza","year":"2024","unstructured":"Antza C, Rizos CV, Kotsis V, Liamis G, Skoumas I, Rallidis L, et al. Familial hypercholesterolemia in the elderly: an analysis of clinical profile and atherosclerotic cardiovascular disease burden from the Hellas-FH Registry. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12010231.","journal-title":"Biomedicines"},{"issue":"5","key":"2328_CR67","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/eurjpc\/zwab185","volume":"29","author":"L Perez de Isla","year":"2022","unstructured":"Perez de Isla L, Watts GF, Muniz-Grijalvo O, Diaz-Diaz JL, Alonso R, Zambon D, et al. A resilient type of Familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort. Eur J Prev Cardiol. 2022;29(5):795\u2013801. https:\/\/doi.org\/10.1093\/eurjpc\/zwab185.","journal-title":"Eur J Prev Cardiol"},{"key":"2328_CR68","doi-asserted-by":"publisher","first-page":"117507","DOI":"10.1016\/j.atherosclerosis.2024.117507","volume":"392","author":"T Melnes","year":"2024","unstructured":"Melnes T, Bogsrud MP, Christensen JJ, Rundblad A, Narverud I, Retterstol K, et al. Gene expression profiling in elderly patients with Familial hypercholesterolemia with and without coronary heart disease. Atherosclerosis. 2024;392:117507. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117507.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2328_CR69","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","volume":"13","author":"JG Robinson","year":"2019","unstructured":"Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019;13(4):525\u201337. https:\/\/doi.org\/10.1016\/j.jacl.2019.05.005.","journal-title":"J Clin Lipidol"},{"issue":"10170","key":"2328_CR70","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists C","year":"2019","unstructured":"Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(18)31942-1.","journal-title":"Lancet"},{"issue":"1","key":"2328_CR71","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13797","volume":"85","author":"R Ofori-Asenso","year":"2019","unstructured":"Ofori-Asenso R, Ilomaki J, Tacey M, Si S, Curtis AJ, Zomer E, et al. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol. 2019;85(1):227\u201335. https:\/\/doi.org\/10.1111\/bcp.13797.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02328-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:55:09Z","timestamp":1772096109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02328-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2328"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02328-2","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"RDS has received honoraria for consulting, research, and\/or speaking activities from Amryt, Amgen, Arrowhead, Biolab, Daiichi-Sankyo, Esperion, Eli Lilly, Ionis, Libbs, MSD, Novo Nordisk, Novartis, PTC Therapeutics, Torrent, Sanofi\/Regeneron, and Ultragenyx. MHM has received payment or honoraria from Ach\u00e9, Novo Nordisk, and Libbs, and financial support for meetings\/travel from Novartis, Eli Lilly, MSD, and Amgen. The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}